RE:RE:RE:RE:RE:RE:RE:RE:We Sit and Waitmenoalittle wrote: If Cancer is near the front of the line in AI research, why hasn't AI still hasn't been able to figure out the primary cause of it?
Oh... so you don't believe me?
Try asking any AI engine if cancer is a genetic disease. Then ask if cancer is a metabolic disease. Then ask whether is it a genetic or a metabolic disease. Then let us know here whether or not AI actually has it figured out...
Evidently there is a lot of intelligent and highly respectable folk that talk like they know and understand a whole lot more about cancer than they honestly do.
One of the most compeling and interesting aspects of Ruvidar (and Rutherrin) that I've thought about... which I don't actually recall ever being made or mentioned in any news release, not by anyone on this forum (or maybe not anywhere else, but I haven't actually looked)... is the difference from chemotherapy in how and why it works.
Unless I'm mistaken (feel free to correct me if so), generally speaking chemotheraphy targets interrupting the genetic reproduction cycle of cancer. Not to say this isn't or can't be effective in varying degrees, depending on a whole host of other hard to pinpoint or understand things. However, take a deep dive into how and why TLD-1433 works (if you haven't already.) When the difference really hits you... then maybe you too will see some of the truth in what a few other posters on this board have claimed... that most investors in Theralase probably still don't come close to really knowing or understanding the value of what they have.
Lot's of problems with mRNA... --------------------------------------------------------------- "As a primary MOA, Rutherrin, has been demonstrated clinically to destroy NMIBC, when activated by light, and preclinically to destroy GBM and Non-Small Cell Lung Cancer ("NSCLC"), when activated by x-ray radiation."